Akram Al-Ibraheem, Serin Moghrabi, Mike Machaba Sathekge, Ahmed Saad Abdlkadir
{"title":"Evaluating Xerostomia as a side effect of [255Ac]Ac-PSMA therapy in prostate cancer: a systematic review and meta-analysis","authors":"Akram Al-Ibraheem, Serin Moghrabi, Mike Machaba Sathekge, Ahmed Saad Abdlkadir","doi":"10.1007/s00259-025-07168-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This systematic review and meta-analysis evaluates xerostomia occurrence in prostate cancer (PC) patients undergoing [<sup>225</sup>Ac]Ac-prostate-specific membrane antigen ([<sup>225</sup>Ac]Ac-PSMA) therapy.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines, comprehensive electronic searches were conducted across PubMed, Scopus, and Web of Science. The study included articles addressing xerostomia as a side effect of [<sup>225</sup>Ac]Ac-PSMA therapy in clinical settings, encompassing both tandem and monotherapy strategies. Methodological quality was assessed using the National Institutes of Health (NIH) Assessment Tool. Stata software was employed to perform pooled xerostomia rates, heterogeneity analysis, meta-regression, and publication bias analysis.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Twenty studies met inclusion criteria, comprising 2949 [<sup>225</sup>Ac]Ac-PSMA cycles administered to 1207 PC patients. For [<sup>225</sup>Ac]Ac-PSMA monotherapy, the pooled rate of any-grade xerostomia was 84% (95%CI: 69–94%). Grade 1–2 xerostomia had a pooled rate 83% (95%CI: 71–93%), while therapy discontinuation due to xerostomia was 5% (95%CI: 0–13%). Grade 3 xerostomia was evident in 13% (95%CI: 7–20%). [<sup>225</sup>Ac]Ac/[<sup>177</sup>Lu]Lu-PSMA tandem therapy resulted in lower pooled rate of 68% for grade 1–2 toxicity (95%CI: 17–100%). Indirect comparison revealed a two-fold decrease in xerostomia risk with tandem protocol compared to monotherapy. Significant heterogeneity was observed, primarily influenced by baseline median prostate-specific antigen values (<i>p</i> = 0.04). Publication bias was present in most xerostomia subgroups, with trim-and-fill analysis adjusting for effect size in specific categories.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Xerostomia is most pronounced in patients undergoing [<sup>225</sup>Ac]Ac-PSMA monotherapy. Tandem approach with [<sup>177</sup>Lu]Lu-PSMA could reduce xerostomia rates and improve compliance. Further large-scale, prospective studies are necessary for generalization and result consolidation.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"82 2 1","pages":""},"PeriodicalIF":8.6000,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07168-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
This systematic review and meta-analysis evaluates xerostomia occurrence in prostate cancer (PC) patients undergoing [225Ac]Ac-prostate-specific membrane antigen ([225Ac]Ac-PSMA) therapy.
Methods
Following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines, comprehensive electronic searches were conducted across PubMed, Scopus, and Web of Science. The study included articles addressing xerostomia as a side effect of [225Ac]Ac-PSMA therapy in clinical settings, encompassing both tandem and monotherapy strategies. Methodological quality was assessed using the National Institutes of Health (NIH) Assessment Tool. Stata software was employed to perform pooled xerostomia rates, heterogeneity analysis, meta-regression, and publication bias analysis.
Results
Twenty studies met inclusion criteria, comprising 2949 [225Ac]Ac-PSMA cycles administered to 1207 PC patients. For [225Ac]Ac-PSMA monotherapy, the pooled rate of any-grade xerostomia was 84% (95%CI: 69–94%). Grade 1–2 xerostomia had a pooled rate 83% (95%CI: 71–93%), while therapy discontinuation due to xerostomia was 5% (95%CI: 0–13%). Grade 3 xerostomia was evident in 13% (95%CI: 7–20%). [225Ac]Ac/[177Lu]Lu-PSMA tandem therapy resulted in lower pooled rate of 68% for grade 1–2 toxicity (95%CI: 17–100%). Indirect comparison revealed a two-fold decrease in xerostomia risk with tandem protocol compared to monotherapy. Significant heterogeneity was observed, primarily influenced by baseline median prostate-specific antigen values (p = 0.04). Publication bias was present in most xerostomia subgroups, with trim-and-fill analysis adjusting for effect size in specific categories.
Conclusion
Xerostomia is most pronounced in patients undergoing [225Ac]Ac-PSMA monotherapy. Tandem approach with [177Lu]Lu-PSMA could reduce xerostomia rates and improve compliance. Further large-scale, prospective studies are necessary for generalization and result consolidation.
期刊介绍:
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.